OmniAb (OABI) Cash from Financing Activities (2021 - 2025)
OmniAb (OABI) reported Cash from Financing Activities of -$50000.0 for Q4 2025, down 101.3% year-over-year from $3.8 million in Q4 2024, and down 100.18% quarter-over-quarter from $27.7 million in Q3 2025.
OmniAb (OABI) Cash from Financing Activities (2021 - 2025) Analysis & Trends
OmniAb (OABI) has 5 years of Cash from Financing Activities data on file, last reported at -$50000.0 in Q4 2025.
- Cash from Financing Activities for Q4 2025 came in at -$50000.0, down 101.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $27.9 million (up 110.07% YoY), and the FY2025 annual result was $27.9 million, up 114.39% from the prior year.
- Cash from Financing Activities fell to -$50000.0 in Q4 2025 per OABI's latest filing, from $27.7 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $237.0 million in Q3 2021 and troughed at -$227.4 million in Q4 2021.
- A 5-year average of $8.9 million and a median of $357000.0 in 2023 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities surged 4912.28% in 2024, then slumped 101.3% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at -$227.4 million in 2021, then surged by 144.5% to $101.2 million in 2022, then plunged by 100.49% to -$496000.0 in 2023, then jumped by 876.01% to $3.8 million in 2024, then plunged by 101.3% to -$50000.0 in 2025.
- Business Quant data shows OABI's Cash from Financing Activities at -$50000.0 in Q4 2025, $27.7 million in Q3 2025, and $236000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | OmniAb | 294.96 Mn | 252.00 Mn | 14.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -50,000.00 |
| Dec 31, 2025 | -50,000.00 |
| Sep 30, 2025 | 27.68 Mn |
| Sep 30, 2025 | 27.68 Mn |
| Jun 30, 2025 | 236,000.00 |
| Jun 30, 2025 | 236,000.00 |
| Mar 31, 2025 | 44,000.00 |
| Mar 31, 2025 | 44,000.00 |
| Dec 31, 2024 | 3.85 Mn |
| Dec 31, 2024 | 3.85 Mn |
| Sep 30, 2024 | 8.57 Mn |
| Sep 30, 2024 | 8.57 Mn |
| Jun 30, 2024 | 803,000.00 |
| Jun 30, 2024 | 803,000.00 |
| Mar 31, 2024 | -203,000.00 |
| Mar 31, 2024 | -203,000.00 |
| Dec 31, 2023 | -496,000.00 |
| Dec 31, 2023 | -496,000.00 |
| Sep 30, 2023 | 171,000.00 |
| Sep 30, 2023 | 171,000.00 |